Latest

Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆

Updated 04 Jul 2026 · HPRA open data

REASSORTANT INFLUENZA VIRUS (LIVE ATTENUATED) B/<OFFICIAL STRAIN> LIKE STRAIN (<ACTUAL STRAIN>) 10^7.0±0.5 FLUORESCENT FOCUS UNITS PER 0.2 ML - Medicines in Ireland

1 authorised product containing REASSORTANT INFLUENZA VIRUS (LIVE ATTENUATED) B/<OFFICIAL STRAIN> LIKE STRAIN (<ACTUAL STRAIN>) 10^7.0±0.5 FLUORESCENT FOCUS UNITS PER 0.2 ML, from the HPRA register.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9

Showing 1 authorised medicines

Medicine	Active substance	Licence holder	Status
Fluenz nasal spray suspension Influenza vaccine (live, nasal) EU/1/24/1816/001-002	REASSORTANT INFLUENZA VIRUS (LIVE ATTENUATED) B/<OFFICIAL STRAIN> LIKE STRAIN (<ACTUAL STRAIN>) 10^7.0±0.5 FLUORESCENT FOCUS UNITS PER 0.2 ML, REASSORTANT INFLUENZA VIRUS (LIVE ATTENUATED) A/<OFFICIAL STRAIN> (H3N2) LIKE STRAIN (<ACTUAL STRAIN>) 10^7.0±0.5 FLUORESCENT FOCUS UNITS PER 0.2 ML, REASSORTANT INFLUENZA VIRUS (LIVE ATTENUATED) A/<OFFICIAL STRAIN> (H1N1) LIKE STRAIN (<ACTUAL STRAIN>) 10^7.0±0.5 FLUORESCENT FOCUS UNITS PER 0.2 ML	AstraZeneca AB	—

Cite this database

Priya Life Science (2026). Irish Medicines Database. Available at: https://priyalifescience.com/medicines (Accessed: 13 September 2026).

Data: Health Products Regulatory Authority (HPRA) open dataset (“Authorised or Transfer Pending Products”), licensed CC BY 4.0, refreshed daily. Regulatory information only — not medical advice.